Back to top
more

Conatus Pharmaceuticals Inc. (CNAT)

(Delayed Data from NSDQ)

$0.33 USD

0.33
266,678

-0.01 (-2.63%)

Updated Nov 20, 2019 03:56 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.62%
17.69%
9.40%
5.11%
2.01%
10.65%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

C Value | C Growth | D Momentum | D VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings?

On GW Pharmaceuticals' (GWPH) first-quarter fiscal 2019 conference call, investor focus will be on the initial sales uptake of its newly approved anti-epileptic drug, Epidiolex.

GWPH CNAT NSTG MGNX

Zacks Equity Research

Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan

Conatus (CNAT) concentrates on the development of its lead candidate emricasan for treating patients with fibrosis or cirrhosis caused by NASH.

PFE NVS BVX CNAT

Zacks Equity Research

The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

CNAT EXEL GILD BIIB IONS

Zacks Equity Research

Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate

A low key week for the biotech sector with focus on regular pipeline updates.

CNAT EXEL GILD BIIB IONS

Zacks Equity Research

Implied Volatility Surging for Conatus (CNAT) Stock Options

Investors need to pay close attention to Conatus (CNAT) stock based on the movements in the options market lately.

CNAT

Zacks Equity Research

Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study

Conatus' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on compensated NASH cirrhosis patients at high risk of decompensation.

NVS PFE BVX CNAT

Zacks Equity Research

Why Is Conatus (CNAT) Up 4.7% Since Last Earnings Report?

Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CNAT

Zacks Equity Research

Do Options Traders Know Something About Conatus (CNAT) Stock We Don't?

Investors need to pay close attention to Conatus (CNAT) stock based on the movements in the options market lately.

CNAT

Zacks Equity Research

Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates

Conatus (CNAT) incurs in-line loss for the third quarter of 2018. Sales miss estimates.

NVS PFE CNAT GILD

Zacks Equity Research

Conatus Pharmaceuticals (CNAT) Reports Q3 Loss, Misses Revenue Estimates

Conatus (CNAT) delivered earnings and revenue surprises of 0.00% and -20.95%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

CNAT

Zacks Equity Research

Options Traders Expect Huge Moves in Conatus Pharmaceuticals (CNAT) Stock

Conatus Pharmaceuticals (CNAT) needs investors to pay close attention to the stock based on moves in the options market lately.

CNAT

Zacks Equity Research

Options Traders Expect Huge Moves in Conatus Pharmaceuticals (CNAT) Stock

Conatus Pharmaceuticals (CNAT) needs investors to pay close attention to the stock based on moves in the options market lately.

CNAT

Zacks Equity Research

Conatus (CNAT) Up 36.2% Since Last Earnings Report: Can It Continue?

Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CNAT

Zacks Equity Research

Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally

Conatus (CNAT) incurs narrower-than-expected loss in Q2. Sales miss estimates.

NVS CNAT EGRX VNDA

Zacks Equity Research

Conatus Pharmaceuticals (CNAT) Reports Q2 Loss, Misses Revenue Estimates

Conatus (CNAT) delivered earnings and revenue surprises of 25.00% and -3.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

CNAT

Zacks Equity Research

What's in the Cards for Conatus (CNAT) This Earnings Season?

On Conatus' (CNAT) second-quarter 2018 conference call, investor focus will remain on the company's progress with respect to its lead candidate, emricasan.

NVS CNAT BDSI ADRO

Ekta Bagri

NASH Space in Focus as Galmed (GLMD) Posts Positive Data

Investor focus is back on the NASH space as quite a few companies release promising data on their NASH candidates of late.

CNAT GILD ICPT GALT

Zacks Equity Research

Why Is Conatus Pharmaceuticals (CNAT) Up 4.1% Since Its Last Earnings Report?

Conatus Pharmaceuticals (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CNAT

Zacks Equity Research

Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates

Conatus (CNAT) reports in-line loss in Q1 while revenues beat estimates. Moreover, the top line improves year over year.

NVS CNAT LGND INFI

Zacks Equity Research

What's in the Cards for Conatus (CNAT) This Earnings Season?

Conatus' (CNAT) might see improvement in Q1 courtesy of its lead candidate emricasan. However, the company's portfolio is devoid of an approved product and its resulting revenues.

NVS CNAT GILD CELG

Zacks Equity Research

Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis

The biotech sector was in the news last week as shares of Spectrum surged on positive data from a phase II study while Incyte plunged on the failure of melanoma study.

NVS ABBV CNAT INCY

Zacks Equity Research

Are Options Traders Betting on a Big Move in Conatus (CNAT) Stock?

Investors in Conatus Pharmaceuticals (CNAT) need to pay close attention to the stock based on moves in the options market lately.

CNAT

Zacks Equity Research

Conatus' Emricasan Fails in Phase II Study, Shares Sink

Conatus Pharmaceuticals' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on liver transplant patients with fibrosis or cirrhosis.

NVS CNAT LGND HZNP

Zacks Equity Research

Conatus (CNAT) Loss Narrower Than Expected in Q4, Sales Miss

Conatus (CNAT) reports narrower-than-expected loss in Q4 while revenues marginally fall short of estimates. However, the top line shows a massive year-over-year increase.

NVS CNAT REGN LGND

Zacks Equity Research

What's in Store for Conatus (CNAT) This Earnings Season?

Conatus' (CNAT) progress with lead candidate emricasan might boost the stock in Q4. However, the company's portfolio lacks an approved product and its revenue generation.

NVS CNAT GEMP APTO